Cytodyn Inc Dr. Pourhassan Discusses Citron Research's False Report Transcript
Hello, and welcome back to Proactive New York. I'm Christine Corrado. With me right now is Nader Pourhassan, CEO at CytoDyn. Nader, great to see you. How are you?
Great. Thanks for having me.
Nader, lots to talk about today. Let's first talk about this note that Citron Research put out. This is a notorious short seller. They basically put out a note that said the SEC must immediately halt this stock promotion scheme, all about CytoDyn. What's your response to that?
So I must say that we don't address these type of false allegation, but because our legal team believe this false report has resulted in unusual market activity or price variation. Therefore, I have been asked to briefly mention some of the false statement in this document.
In the first two sentences of this report, there were six false statement
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
